| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911656 | Lung Cancer | 2005 | 8 Pages |
Abstract
: The combination of irinotecan/docetaxel is a relatively active non-platinum-based chemotherapy regimen with manageable toxicity, which could be given in an outpatient basis; this regimen merits to be further studied in order to improve its tolerance and evaluate its clinical relevance in patients who can not tolerate platinum-based doublets.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Panagiotis Ziotopoulos, Nikolaos Androulakis, Efthimia Mylonaki, Vassilios Chandrinos, Emmanouel Zachariadis, Ioannis Boukovinas, Athina Agelidou, Nikolaos Kentepozidis, Michail Ignatiadis, Andreas Vossos, Vassilis Georgoulias,